Antibody-drug conjugates: beyond current approvals and potential future strategies

Siddharth Menon; Sagun Parakh; Andrew M Scott; Hui K Gan

doi:10.37349/etat.2022.00082

Antibody-drug conjugates: beyond current approvals and potential future strategies

Explor Target Antitumor Ther. 2022;3(2):252-277. doi: 10.37349/etat.2022.00082. Epub 2022 Apr 28.

Authors

Siddharth Menon^{1

2}, Sagun Parakh^{1

2}, Andrew M Scott^{1

2}, Hui K Gan^{1

2}

Affiliations

¹ Olivia Newton-John Cancer Centre at Austin Health, Olivia Newton-John Cancer Wellness & Research Centre, Heidelberg Victoria 3084, Australia.
² College of Science, Health and Engineering, La Trobe University, Melbourne Victoria 3086, Australia.

Abstract

The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits of high specific targeting of oncogenic cell surface antigens with the additional cell kill from high potency cytotoxic payloads, thus achieving wider therapeutic windows. This review will summarise the clinical activity of ADCs in tumour types not covered elsewhere in this issue, such as gastrointestinal (GI) and genitourinary (GU) cancers and glioblastoma (GBM). In addition to the ongoing clinical testing of existing ADCs, there is substantial preclinical and early phase testing of newer ADCs or ADC incorporating strategies. This review will provide selected insights into such future development, focusing on the development of novel ADCs against new antigen targets in the tumour microenvironment (TME) and combination of ADCs with immuno-oncology (IO) agents.

Keywords: Antibody-drug conjugates; immunotherapy; tumour microenvironment.

Publication types

Review